Overview

Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
A phase 2 study to assess the MVA smallpox vaccine in previously vaccinated and vaccine- naive subjects at three dose levels.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi Pasteur, a Sanofi Company
Treatments:
Vaccines